Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTKWUM)

• Drug Name: N-(2-aminophenyl)-4-methoxybenzamide Drug Info
• Synonyms: N-(2-aminophenyl)-4-methoxybenzamide; AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 785232
  CAS Number: CAS 103517-57-3
  TTD Drug ID: DMTKWUM

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 2 (HDAC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CHR-3996	DMIXPNG	Lymphoma	2A80-2A86	Phase 1/2	[2]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[3]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[3]

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[4]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[5]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[8]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[9]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[6]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[11]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[12]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[13]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[14]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[13]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[12]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[15]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[16]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[17]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[13]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[1]
Histone deacetylase 2 (HDAC2)	TTSHTOI	HDAC2_HUMAN	Inhibitor	[1]

References

• [1] Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
• [2] A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
• [3] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [4] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [5] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [9] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [10] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [11] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [14] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [15] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [16] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [17] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [18] 2011 Pipeline of 4SC AG.